![nr-axSpA](https://www.adcreviews.com/wp-content/uploads/2022/08/nr-axSpA-300x225.jpeg)
First JAK inhibitor approved for nr-axSpA patients
On July 29, AbbVie announced that the European Commission (EC) has approved upatinib (15 mg once daily) for the treatment of adults with active non-radiographic
On July 29, AbbVie announced that the European Commission (EC) has approved upatinib (15 mg once daily) for the treatment of adults with active non-radiographic
On July 19, Incyte announced that the FDA approved ruxolitinib cream 1.5% for the topical treatment of non-segmental vitiligo in adults and children over 12